Gilead Sciences, Inc. vs Innodata Inc — how do they compare? Gilead Sciences, Inc. trades at $135.64 (market cap $168.35B), while Innodata Inc trades at $62.04 (market cap $2.05B). The key difference: Gilead Sciences, Inc. is far larger — about 82.1× Innodata Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.
| GILD | INOD | |
|---|---|---|
Market Cap | $168.35B | $2.05B |
Sector | Health | Technology |
52-Week High | $155.80 | $121.50 |
52-Week Low | $110.56 | $34.45 |
Enterprise Value | $191.42B | $1.80B |
Dividend Yield | 2.42% | — |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
INOD trades at $62.26, up 0.06% on the day, with a bullish technical signal supported by oscillators and strong momentum indicators. The company reported robust Q2 2026 results, beating EPS estimates with $0.41 versus $0.21 expected, driven by 58% revenue growth and margin expansion. Analyst consensus is bullish with a $130 price target, reflecting optimism around AI-driven growth and profitability improvements.
Outlook remains positive due to accelerating AI demand and operational leverage, though the stock's premium valuation (P/E 48.62) poses a risk if growth moderates. Key opportunities include continued AI adoption and customer diversification, while risks involve execution challenges and competitive pressures in the AI services sector.
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →